J Thorac Dis:肺移植后的眼科并发症

2019-01-19 MedSci MedSci原创

美国俄亥俄州阿克伦市克利夫兰诊所Akron General内科的Dhal U及Cole眼科研究所的Raju S等人近日在J Thorac Dis杂志上发表了一篇重要综述文章,作者系统论述了肺移植后的眼科并发症。

美国俄亥俄州阿克伦市克利夫兰诊所Akron General内科的Dhal U及Cole眼科研究所的Raju S等人近日在J Thorac Dis杂志上发表了一篇重要综述文章,作者系统论述了肺移植后的眼科并发症。

肺移植人群中的眼科并发症是鲜为人知的。这包括一系列疾病,从巨细胞病毒(CMV)视网膜炎、疱疹性角膜炎、假性疟原虫感染到非感染性并发症如后囊下白内障(PSCs)、环孢菌素视网膜病变和移植后淋巴组织增生性疾病(PTLD)等。这些疾病可能是由于高水平的免疫抑制、高龄和药物特异性副作用等原因造成。糖尿病等潜在的并发症也可能在发病机制中发挥了重要作用。患者可能出现各种症状,如视力模糊、混浊物或眼睛疼痛等。

只有高度警觉性的患者才能及时就医诊断。作者提醒,随着越来越多的移植手术在全球范围内进行,肺病专家和移植医生必须认识到这些常常是微妙的症状。任何视觉症状都应进行眼科检查,以便控制这些并发症,因为其中一些会带来系统性扩散和重大发病率的风险。

文章深入回顾了与肺移植后常见眼科并发症相关的常见症状、治疗方法和最新进展。虽然本文侧重于肺移植的患者群体,但作者指出,其他一些类似免疫抑制疗法治疗的实体器官移植病例,也可以借鉴其中一些并发症。

原文出处:

Dhal, U., et al., "For your eyes only": ophthalmic complications following lung transplantation. J Thorac Dis, 2018. 10(11): p. 6285-6297.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057045, encodeId=3a8c205e045fa, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Jun 23 10:32:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758071, encodeId=98e01e5807132, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 14 10:32:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012919, encodeId=a6162012919d2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 05 21:32:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358661, encodeId=3eea3586614d, content=很新颖的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Sat Jan 19 22:16:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-06-23 yyj062
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057045, encodeId=3a8c205e045fa, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Jun 23 10:32:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758071, encodeId=98e01e5807132, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 14 10:32:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012919, encodeId=a6162012919d2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 05 21:32:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358661, encodeId=3eea3586614d, content=很新颖的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Sat Jan 19 22:16:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-03-14 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057045, encodeId=3a8c205e045fa, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Jun 23 10:32:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758071, encodeId=98e01e5807132, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 14 10:32:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012919, encodeId=a6162012919d2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 05 21:32:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358661, encodeId=3eea3586614d, content=很新颖的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Sat Jan 19 22:16:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057045, encodeId=3a8c205e045fa, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Jun 23 10:32:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758071, encodeId=98e01e5807132, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Mar 14 10:32:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012919, encodeId=a6162012919d2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 05 21:32:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358661, encodeId=3eea3586614d, content=很新颖的研究点, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Sat Jan 19 22:16:00 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-19 若轩

    很新颖的研究点

    0

相关资讯

Sci Transl Med:移植生物工程肺

德克萨斯大学医学分部的一个研究小组将具有功能的生物工程肺移植到成年猪体内,术后未出现医疗并发症。

中国肺移植供体标准及获取转运指南

2015 年我国供肺利用率仅约5%。从器官获取组织(OPO)进行供肺协调、初步评估和维护,到供肺获取直至最后经民航、高速公路、高铁转运完成肺移植,每一环节都相当艰难。许多初评合格的供肺,由于缺乏有效的维护而无法用于移植。因此,我们组织专家制订我国肺移植供体标准及获取转运指南,从我国肺移植供肺捐献的分类、供肺选择标准、供肺维护策略、供肺获取流程、供肺转运流程等方面,总结我国肺移植的临床实践经验,希望

Thorax:等待肺移植患者的结局

英国供体肺分配的方式导致了风险概况与肺移植概率之间存在差异。

中国肺移植数量跃居全球领先,但只用了不到5%的捐献肺器官

12月19日,记者从中日医院肺移植百例工作总结会上获悉,今年以来,中日医院肺移植中心已完成104例肺移植,无锡人民医院肺移植中心完成140多例肺移植,中国肺移植数量已经跃居全球第一。一人肩挑两大肺移植中心提到中国肺移植,一定绕不开一个人——无锡市人民医院副院长、中日医院肺移植中心副主任陈静瑜,他也被称为中国肺移植第一人。2017年中国肺移植注册系统共上报肺移植手术299例,由陈静瑜领导的团队完成了

Chest:肺分配评分阈值优先考虑肺移植后的存活率

初始LAS≥70患者的LTx生存获益一致。该结果支持对LAS≥70患者进行供体肺分配的优先级平等化。

PLos One:肺移植受者肺和血浆病毒基因组的时间动态

广泛的病毒株共存于LTRs的BAL和血浆中。尤其是anellovirus病毒,观察到移植后高度的共感染和个体化复杂动态。